← Back to Screener
Acurx Pharmaceuticals, Inc. Common Stock (ACXP)
Price$2.49
Favorite Metrics
Price vs S&P 500 (26W)-65.71%
Price vs S&P 500 (4W)-46.32%
Market Capitalization$8.85M
All Metrics
Book Value / Share (Quarterly)$2.24
P/TBV (Annual)7.28x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.89
Price vs S&P 500 (YTD)21.86%
EPS (TTM)$-5.99
10-Day Avg Trading Volume0.16M
EPS Excl Extra (TTM)$-5.99
EPS (Annual)$-5.32
ROI (Annual)-151.21%
Cash / Share (Quarterly)$3.22
ROA (Last FY)-103.60%
EBITD / Share (TTM)$-5.39
ROE (5Y Avg)-604.85%
Cash Flow / Share (Annual)$-2.89
P/B Ratio1.68x
P/B Ratio (Quarterly)0.99x
Net Income / Employee (Annual)$-2
ROA (TTM)-128.71%
EPS Incl Extra (Annual)$-5.32
Current Ratio (Annual)3.18x
Quick Ratio (Quarterly)3.14x
3-Month Avg Trading Volume2.16M
52-Week Price Return-59.48%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.30
52-Week High$21.00
EPS Excl Extra (Annual)$-5.32
26-Week Price Return-61.73%
Quick Ratio (Annual)3.14x
13-Week Price Return11.51%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.18x
Enterprise Value$1.295
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.22
3-Month Return Std Dev282.37%
Net Income / Employee (TTM)$-2
ROE (Last FY)-151.21%
EPS Basic Excl Extra (Annual)$-5.32
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.99
ROI (TTM)-215.55%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.63
Price vs S&P 500 (52W)-89.31%
Year-to-Date Return24.50%
5-Day Price Return15.24%
EPS Normalized (Annual)$-5.32
ROA (5Y Avg)-176.68%
Month-to-Date Return-16.44%
Cash Flow / Share (TTM)$-0.78
EBITD / Share (Annual)$-5.40
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-604.85%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-5.99
P/TBV (Quarterly)13.54x
P/B Ratio (Annual)0.99x
Book Value / Share (Annual)$2.24
Price vs S&P 500 (13W)10.82%
Beta-1.95x
Revenue / Share (TTM)$0.00
ROE (TTM)-215.55%
52-Week Low$1.33
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ACXPAcurx Pharmaceuticals, Inc. Common Stock | — | — | — | — | $2.49 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel antibiotics for serious infections caused by priority pathogens identified by the WHO, CDC, and FDA. The company's platform targets Gram-positive bacteria and includes both clinical and preclinical drug candidates.